Dr. Edward J. Kim
Claim this profileUniversity of California Davis Comprehensive Cancer Center
Studies Cancer
Studies Adenocarcinoma
30 reported clinical trials
68 drugs studied
About Edward J. Kim
Education:
- Earned an A.B. in Chemistry from Harvard University, Cambridge, MA (1997).
- Received M.D. and Ph.D. from Stony Brook University, Stony Brook, NY (2005, 2003 respectively).
Experience:
- Completed Internal Medicine Residency and Hematology/Oncology Fellowship at the University of Michigan, Ann Arbor, MI (2005-2011).
- Serves as Medical Director at UC Davis Comprehensive Cancer Center’s Office of Clinical Research.
- Holds the position of Associate Professor of Medicine, specializing in gastrointestinal malignancies.
- Actively involved in clinical and laboratory research, focusing on novel treatments and patient-derived models for pancreatic cancer.
Area of expertise
1Cancer
Stage IV
Stage III
PD-L1 positive
2Adenocarcinoma
Stage IV
PD-L1 positive
hCG positive
Affiliated Hospitals
Clinical Trials Edward J. Kim is currently running
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Triapine + Targeted Radiation
for Neuroendocrine Cancer
This phase II trial compares the effect of adding triapine to lutetium Lu 177 dotatate versus lutetium Lu 177 dotatate alone (standard therapy) in shrinking tumors or slowing tumor growth in patients with neuroendocrine tumors that have spread from where they first started (primary site) to other places in the body (metastatic). Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for deoxyribonucleic acid synthesis and cell growth. Lutetium Lu 177 dotatate is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. Lutetium Lu 177 dotatate builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. Giving triapine in combination with lutetium Lu 177 dotatate may be more effective at shrinking tumors or slowing tumor growth in patients with metastatic neuroendocrine tumors than the standard therapy of lutetium Lu 177 dotatate alone.
Recruiting1 award Phase 2
More about Edward J. Kim
Clinical Trial Related1 year of experience running clinical trials · Led 30 trials as a Principal Investigator · 20 Active Clinical TrialsTreatments Edward J. Kim has experience with
- Nivolumab
- Cisplatin
- Gemcitabine
- Nab-paclitaxel
- Radiation Therapy
- Hypofractionated Radiation Therapy
Breakdown of trials Edward J. Kim has run
Cancer
Adenocarcinoma
Pancreatic Cancer
Gallbladder Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Edward J. Kim specialize in?
Edward J. Kim focuses on Cancer and Adenocarcinoma. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is Edward J. Kim currently recruiting for clinical trials?
Yes, Edward J. Kim is currently recruiting for 18 clinical trials in Sacramento California. If you're interested in participating, you should apply.
Are there any treatments that Edward J. Kim has studied deeply?
Yes, Edward J. Kim has studied treatments such as Nivolumab, Cisplatin, Gemcitabine.
What is the best way to schedule an appointment with Edward J. Kim?
Apply for one of the trials that Edward J. Kim is conducting.
What is the office address of Edward J. Kim?
The office of Edward J. Kim is located at: University of California Davis Comprehensive Cancer Center, Sacramento, California 95817 United States. This is the address for their practice at the University of California Davis Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.